2.73
+0.11(+4.20%)
Currency In USD
| Previous Close | 2.62 |
| Open | 2.6 |
| Day High | 2.73 |
| Day Low | 2.53 |
| 52-Week High | 4.18 |
| 52-Week Low | 2.25 |
| Volume | 27,057 |
| Average Volume | 483,211 |
| Market Cap | 9.37M |
| PE | -0.81 |
| EPS | -3.36 |
| Moving Average 50 Days | 2.85 |
| Moving Average 200 Days | 3.2 |
| Change | 0.11 |
If you invested $1000 in Kiora Pharmaceuticals, Inc. (KPRX) 10 years ago, it would be worth $0.13 as of August 23, 2025 at a share price of $2.73. Whereas If you bought $1000 worth of Kiora Pharmaceuticals, Inc. (KPRX) shares 5 years ago, it would be worth $1.67 as of August 23, 2025 at a share price of $2.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Newsfile
Aug 07, 2025 11:00 AM GMT
Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's pipeline of therapies targeting inherited and inflamm
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease
Newsfile
Jul 22, 2025 12:55 PM GMT
Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment of a wide range of ocular diseases. This inclu
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
Newsfile
Jun 03, 2025 11:00 AM GMT
Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single digit million up-front payment, development, regulatory,